These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 22554357)

  • 41. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group.
    Falagas ME; Snydman DR; Ruthazer R; Griffith J; Werner BG; Freeman R; Rohrer R
    Clin Transplant; 1997 Oct; 11(5 Pt 1):432-7. PubMed ID: 9361936
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Time of acquisition of HCV infection in renal transplant recipients: a major prognostic factor for disease progression.
    Delladetsima I; Psichogiou M; Sypsa V; Sakellariou S; Hatzakis A; N Boletis J
    Clin Transplant; 2013; 27(1):72-9. PubMed ID: 22994949
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Preoperative Cylex assay predicts rejection risk in patients with kidney transplant.
    Myslik F; House AA; Yanko D; Warren J; Caumartin Y; Rehman F; Jevnikar AM; Stitt L; Luke PP
    Clin Transplant; 2014 May; 28(5):606-10. PubMed ID: 24628326
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The importance of clinical parameters when differentiating cholestatic hepatitis C virus from allograft rejection.
    Neff GW; Shire N; Ruiz P; O'Brien C; Garcia M; Dela Garza J; Rudich SR; Reddy KR
    Transplant Proc; 2005 Dec; 37(10):4397-402. PubMed ID: 16387130
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Incidence of rejection and infection after liver transplantation as a function of the primary disease: possible influence of alcohol and polyclonal immunoglobulins.
    Farges O; Saliba F; Farhamant H; Samuel D; Bismuth A; Reynes M; Bismuth H
    Hepatology; 1996 Feb; 23(2):240-8. PubMed ID: 8591847
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Early tacrolimus exposure after liver transplantation: relationship with moderate/severe acute rejection and long-term outcome.
    Rodríguez-Perálvarez M; Germani G; Papastergiou V; Tsochatzis E; Thalassinos E; Luong TV; Rolando N; Dhillon AP; Patch D; O'Beirne J; Thorburn D; Burroughs AK
    J Hepatol; 2013 Feb; 58(2):262-70. PubMed ID: 23023010
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Assessing the risk of infection and rejection in Hispanic renal transplant recipients by means of an adenosine triphosphate release assay.
    Cadillo-Chávez R; de Echegaray S; Santiago-Delpín EA; Rodríguez-Trinidad AT; Camacho-Carrazo B; Alfaro T; Saavedra-Pozo M; Carrasquillo L; González-Caraballo ZA; Morales-Otero LA
    Transplant Proc; 2006 Apr; 38(3):918-20. PubMed ID: 16647510
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Trial of complete weaning from immunosuppression for liver transplant recipients: factors predictive of tolerance.
    de la Garza RG; Sarobe P; Merino J; Lasarte JJ; D'Avola D; Belsue V; Delgado JA; Silva L; Iñarrairaegui M; Sangro B; Sola JJ; Pardo F; Quiroga J; Herrero JI
    Liver Transpl; 2013 Sep; 19(9):937-44. PubMed ID: 23784747
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of immunosuppression on immunopathogenesis of liver damage in hepatitis C virus-infected recipients following liver transplantation.
    McCaughan GW; Zekry A
    Liver Transpl; 2003 Nov; 9(11):S21-7. PubMed ID: 14586891
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of anti-hepatitis C virus (HCV) antibody on outcomes in renal transplant recipients infected with HCV.
    Minz M; Sharma A; Das A; Chawla Y
    Transplant Proc; 2008 Sep; 40(7):2386-8. PubMed ID: 18790242
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Successful withdrawal of prednisone after adult liver transplantation for autoimmune hepatitis.
    Trouillot TE; Shrestha R; Kam I; Wachs M; Everson GT
    Liver Transpl Surg; 1999 Sep; 5(5):375-80. PubMed ID: 10477838
    [TBL] [Abstract][Full Text] [Related]  

  • 53. ImmuKnow: a new parameter in immune monitoring of pediatric liver transplantation recipients.
    Israeli M; Klein T; Sredni B; Avitzur Y; Mor E; Bar-Nathen N; Steinberg R; Dinari G; Shapiro R
    Liver Transpl; 2008 Jun; 14(6):893-8. PubMed ID: 18508374
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database.
    Watt KD; Dierkhising R; Heimbach JK; Charlton MR
    Liver Transpl; 2012 Sep; 18(9):1029-36. PubMed ID: 22641474
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival.
    Pretagostini R; Cinti P; Lai Q; Poli L; Berloco PB
    Transpl Immunol; 2008 Nov; 20(1-2):3-5. PubMed ID: 18773959
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Retransplantation for late liver graft failure: predictors of mortality.
    Facciuto M; Heidt D; Guarrera J; Bodian CA; Miller CM; Emre S; Guy SR; Fishbein TM; Schwartz ME; Sheiner PA
    Liver Transpl; 2000 Mar; 6(2):174-9. PubMed ID: 10719016
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression.
    Berenguer M; Aguilera V; Prieto M; San Juan F; Rayón JM; Benlloch S; Berenguer J
    J Hepatol; 2006 Apr; 44(4):717-22. PubMed ID: 16487616
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Steroid-free immunosuppression after liver transplantation does not increase the risk of graft fibrosis.
    Manzia TM; Toti L; Angelico R; Di Cocco P; Orlando G; Tisone G
    Transplant Proc; 2010 May; 42(4):1237-9. PubMed ID: 20534270
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A randomized, placebo-controlled trial with anti-interleukin-2 receptor antibody for immunosuppressive induction therapy after liver transplantation.
    Langrehr JM; Glanemann M; Guckelberger O; Klupp J; Neumann U; Machens C; Lohmann R; Knoop M; Lobeck H; Schlag H; Keck H; Settmacher U; Bechstein WO; Neuhaus PJ
    Clin Transplant; 1998 Aug; 12(4):303-12. PubMed ID: 9686324
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antibody response to hepatitis C virus infection after liver transplantation.
    Hsu HH; Wright TL; Tsao SC; Combs C; Donets M; Feinstone SM; Greenberg HB
    Am J Gastroenterol; 1994 Aug; 89(8):1169-74. PubMed ID: 7519818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.